Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.
종목 코드 AMPH
회사 이름Amphastar Pharmaceuticals Inc
상장일Jun 25, 2014
CEODr. Yongfeng (Jack) Zhang, Ph.D.
직원 수2028
유형Ordinary Share
회계 연도 종료Jun 25
주소11570 6th St
도시RANCHO CUCAMONGA
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호91730
전화19099809484
웹사이트https://amphastar.com/
종목 코드 AMPH
상장일Jun 25, 2014
CEODr. Yongfeng (Jack) Zhang, Ph.D.
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음